New cell therapy aims to supercharge Kids' immune cells after transplant
NCT ID NCT07518654
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new cell therapy called ThINKK in 12 children aged 2–12 who have had a stem cell transplant for leukemia or neuroblastoma. The therapy is designed to boost the body's natural killer (NK) cells to better fight cancer. The main goals are to check if the treatment is safe and feasible, and to see how the immune system responds.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Sainte-Justine
Montreal, Quebec, H3T1C5, Canada
-
The Hospital for Sick Children
Toronto, Ontario, M5G1E8, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a targeted pill turn the tide against a bone marrow disorder?
- Can a shorter chemo combo tame High-Risk neuroblastoma?
- Can a radioactive 'Smart Bomb' take down resistant childhood cancers?
- Could a platelet-boosting drug shorten recovery after stem cell transplants?